CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office
April 28 2017 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) today announced that
it has been notified that it will be granted a new patent on
Multikine* (Leukocyte Interleukin, Injection), its investigational
cancer immunotherapy, from the European Patent Office. The patent
is titled: A METHOD FOR MODULATING HLA CLASS II TUMOR CELL SURFACE
EXPRESSION WITH A CYTOKINE MIXTURE.
The patent relates to a method for altering the composition of
tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio,
increasing tumor stroma/epithelial ratio, and modulating HLA (Human
Leukocyte Antigen) class II expression on a tumor cell surface with
Multikine. CEL-SCI believes that this will result in the tumor
becoming “visible” to the immune system, culminating in a more
robust and sustainable anti-tumor immune response.
Geert Kersten, CEL-SCI Chief Executive Officer, said, “Our
patent portfolio for Multikine consists of multiple patents issued
in the United States, Europe, China and Japan. In addition to these
patents that offer certain protections for Multikine, the method of
manufacture for Multikine held by CEL-SCI as trade secret offers
additional protections.”
About Multikine
Multikine is designed to be a different type of therapy against
cancer: one that appears to have the potential to work with the
body's natural immune system in the fight against tumors. Multikine
is an investigational immunotherapeutic agent that is being tested
in an open-label, randomized, controlled, global pivotal Phase 3
clinical trial as a potential first-line treatment for advanced
primary squamous cell carcinoma of the head and neck. The Phase 3
study with Multikine, which remains on partial clinical hold for
the enrollment of additional patients, has 928 patients
enrolled.
Multikine is also being tested in a Phase 1 study at the
University of California, San Francisco (UCSF), as a potential
treatment for peri-anal warts in HIV/HPV co-infected men and women.
Dr. Joel Palefsky, a world-renowned scientist and Key Opinion
Leader in human papilloma virus (HPV) research and the prevention
of anal cancer, is the Principal Investigator at UCSF.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. The
Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Such statements include, but are not limited to, statements about
the terms, expected proceeds, use of proceeds and closing of the
offering. Factors that could cause or contribute to such
differences include, an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to
raise the necessary capital and the risk factors set forth from
time to time in CEL-SCI's filings with the Securities and Exchange
Commission, including but not limited to its report on Form 10-K
and 10-K/A for the year ended September 30, 2016. The Company
undertakes no obligation to publicly release the result of any
revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress and that
is currently subject to a clinical hold on enrollment of additional
new patients.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170428005105/en/
CEL-SCI CorporationGavin de Windt,
703-506-9460www.cel-sci.com
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024